189 related articles for article (PubMed ID: 32229739)
1. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
Helbert A; Von Wronski M; Colevret D; Botteron C; Padilla F; Bettinger T; Tardy I; Hyvelin JM
Invest Radiol; 2020 Oct; 55(10):657-665. PubMed ID: 32229739
[TBL] [Abstract][Full Text] [Related]
2. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
[TBL] [Abstract][Full Text] [Related]
3. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.
Tardy I; Pochon S; Theraulaz M; Emmel P; Passantino L; Tranquart F; Schneider M
Invest Radiol; 2010 Oct; 45(10):573-8. PubMed ID: 20808233
[TBL] [Abstract][Full Text] [Related]
5. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
[TBL] [Abstract][Full Text] [Related]
6. The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55).
Bzyl J; Palmowski M; Rix A; Arns S; Hyvelin JM; Pochon S; Ehling J; Schrading S; Kiessling F; Lederle W
Eur Radiol; 2013 Feb; 23(2):468-75. PubMed ID: 22878592
[TBL] [Abstract][Full Text] [Related]
7. Quantification in molecular ultrasound imaging: a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft.
Sugimoto K; Moriyasu F; Negishi Y; Hamano N; Oshiro H; Rognin NG; Yoshida T; Kamiyama N; Aramaki Y; Imai Y
J Ultrasound Med; 2012 Dec; 31(12):1909-16. PubMed ID: 23197543
[TBL] [Abstract][Full Text] [Related]
8. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.
Eschbach RS; Clevert DA; Hirner-Eppeneder H; Ingrisch M; Moser M; Schuster J; Tadros D; Schneider M; Kazmierczak PM; Reiser M; Cyran CC
PLoS One; 2017; 12(1):e0169323. PubMed ID: 28060884
[TBL] [Abstract][Full Text] [Related]
9. Quantitative ultrasound molecular imaging by modeling the binding kinetics of targeted contrast agent.
Turco S; Tardy I; Frinking P; Wijkstra H; Mischi M
Phys Med Biol; 2017 Mar; 62(6):2449-2464. PubMed ID: 28240217
[TBL] [Abstract][Full Text] [Related]
10. Effects of acoustic radiation force on the binding efficiency of BR55, a VEGFR2-specific ultrasound contrast agent.
Frinking PJ; Tardy I; Théraulaz M; Arditi M; Powers J; Pochon S; Tranquart F
Ultrasound Med Biol; 2012 Aug; 38(8):1460-9. PubMed ID: 22579540
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.
Wang H; Kaneko OF; Tian L; Hristov D; Willmann JK
Invest Radiol; 2015 May; 50(5):322-9. PubMed ID: 25575176
[TBL] [Abstract][Full Text] [Related]
12. First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study.
Smeenge M; Tranquart F; Mannaerts CK; de Reijke TM; van de Vijver MJ; Laguna MP; Pochon S; de la Rosette JJMCH; Wijkstra H
Invest Radiol; 2017 Jul; 52(7):419-427. PubMed ID: 28257340
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).
Pysz MA; Foygel K; Rosenberg J; Gambhir SS; Schneider M; Willmann JK
Radiology; 2010 Aug; 256(2):519-27. PubMed ID: 20515975
[TBL] [Abstract][Full Text] [Related]
14. Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment.
Grouls C; Hatting M; Rix A; Pochon S; Lederle W; Tardy I; Kuhl CK; Trautwein C; Kiessling F; Palmowski M
Radiology; 2013 May; 267(2):487-95. PubMed ID: 23360735
[TBL] [Abstract][Full Text] [Related]
15. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
[TBL] [Abstract][Full Text] [Related]
16. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38).
Bzyl J; Lederle W; Rix A; Grouls C; Tardy I; Pochon S; Siepmann M; Penzkofer T; Schneider M; Kiessling F; Palmowski M
Eur Radiol; 2011 Sep; 21(9):1988-95. PubMed ID: 21562807
[TBL] [Abstract][Full Text] [Related]
17. Improved Detection of preclinical Colorectal Liver Metastases by High Resolution Ultrasound including Molecular Ultrasound Imaging using the targeted Contrast Agent BR55.
Hackl C; Schacherer D; Anders M; Wiedemann LM; Mohr A; Schlitt HJ; Stroszczynski C; Tranquart F; Jung EM
Ultraschall Med; 2016 Jun; 37(3):290-6. PubMed ID: 27112624
[TBL] [Abstract][Full Text] [Related]
18. A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature.
Warram JM; Sorace AG; Saini R; Umphrey HR; Zinn KR; Hoyt K
J Ultrasound Med; 2011 Jul; 30(7):921-31. PubMed ID: 21705725
[TBL] [Abstract][Full Text] [Related]
19. Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.
Baron Toaldo M; Salvatore V; Marinelli S; Palamà C; Milazzo M; Croci L; Venerandi L; Cipone M; Bolondi L; Piscaglia F
Mol Imaging Biol; 2015 Feb; 17(1):29-37. PubMed ID: 25082536
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
